Skip to Main Content

WASHINGTON — The Trump administration’s Tuesday agreement on a new trade deal with Canada and Mexico is very bad news for the drug industry.

The newly unveiled deal, commonly known as USMCA, will not have any protection for high-tech biologic drugs, which are made from living cells. That’s a huge break from the first version of the deal, which was unveiled in late September 2018 and included 10 years of exclusivity protection for these drugs. That provision was removed as part of an effort to appease House Democrats, who must approve the trade deal before it can be ratified.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.